At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
03759 PHARMARON
Not Yet Opened 04-08 16:08:19
20.640
-0.340
-1.62%
High21.580Low20.280Vol8.88M
Open21.320D1 Closing20.980Amplitude6.20%
Mkt Cap37.77BTradable Cap7.29BTotal Shares1.83B
T/O184.59MT/O Rate2.51%Tradable Shares353.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
IEA Warns of Doubling Oil Supply Gap in April; US Launches Manned Moon Mission Rocket
Stock News  ·  04-02
IEA Warns of Doubling Oil Supply Gap in April; US Launches Manned Moon Mission Rocket
Stock Track | PHARMARON Soars 11.69% Intraday on Strong Q4 Earnings and Robust New Order Growth
Stock Track  ·  04-01
Stock Track | PHARMARON Soars 11.69% Intraday on Strong Q4 Earnings and Robust New Order Growth
PHARMARON Shares Surge Over 7% on Strong Performance Acceleration and Double-Digit New Order Growth
Stock News  ·  04-01
PHARMARON Shares Surge Over 7% on Strong Performance Acceleration and Double-Digit New Order Growth
Stock Track | PHARMARON Soars 5.09% Intraday on Capital Increase and Dividend Proposal
Stock Track  ·  03-31
Stock Track | PHARMARON Soars 5.09% Intraday on Capital Increase and Dividend Proposal
PHARMARON Proposes Capital Increase
Stock News  ·  03-31
PHARMARON Proposes Capital Increase
Pharmaron Reports 2025 Financial Results with Net Profit Decline
Stock News  ·  03-30
Pharmaron Reports 2025 Financial Results with Net Profit Decline
Pharmaron to Elevate Registered Capital to RMB 1.84 Billion and Appoints New Company Secretary
Bulletin Express  ·  03-30
Pharmaron to Elevate Registered Capital to RMB 1.84 Billion and Appoints New Company Secretary
Pharmaron Proposes Final Cash Dividend of RMB2 per 10 Shares for FY2025
Bulletin Express  ·  03-30
Pharmaron Proposes Final Cash Dividend of RMB2 per 10 Shares for FY2025
HK Pharma Stocks Gained. CSPC Pharma Up 13%; Lepu Bio Up 7%; Hengrui Pharma And Junshi Bio Up 6%; HBM, Beigene, Sihuan Pharm Up 5%
Tiger Newspress  ·  03-27
HK Pharma Stocks Gained. CSPC Pharma Up 13%; Lepu Bio Up 7%; Hengrui Pharma And Junshi Bio Up 6%; HBM, Beigene, Sihuan Pharm Up 5%
Beijing Economic Zone Launches Two New Bus Routes Today
Deep News  ·  03-26
Beijing Economic Zone Launches Two New Bus Routes Today
HK Pharma Stocks Gained. XuanzhuBio Up 9%; Xtalpi, Lepu Bio And Ascletis Up 6%; Akeso Up 5%; Skb Bio Up 4%.
Tiger Newspress  ·  03-26
HK Pharma Stocks Gained. XuanzhuBio Up 9%; Xtalpi, Lepu Bio And Ascletis Up 6%; Akeso Up 5%; Skb Bio Up 4%.
HK Pharma Stocks Gained. Wuxi XDC Up 8%; Wuxi AppTec Up 7%; Transthera And HBM Up 5%; Keymed Bio And Innocare Up 4%; Wuxi Bio And Remegen Up 3%
Tiger Newspress  ·  03-24
HK Pharma Stocks Gained. Wuxi XDC Up 8%; Wuxi AppTec Up 7%; Transthera And HBM Up 5%; Keymed Bio And Innocare Up 4%; Wuxi Bio And Remegen Up 3%
UBS: Supply Chain Disruptions in Petrochemical Downstream Products Could Benefit Chinese Companies
Stock News  ·  03-23
UBS: Supply Chain Disruptions in Petrochemical Downstream Products Could Benefit Chinese Companies
Norges Bank Increases Stake in Pharmaron with 557,500 Shares at HK$19.60 Each
Stock News  ·  03-17
Norges Bank Increases Stake in Pharmaron with 557,500 Shares at HK$19.60 Each
HK Movers | Biotech Stocks Jump. Wuxi XDC up 7%; Junshi Bio up 6%; Remegen, Genscript Bio, Wuxi Apptec up around 5%; Innocare up over 4%.
Tiger Newspress  ·  03-17
HK Movers | Biotech Stocks Jump. Wuxi XDC up 7%; Junshi Bio up 6%; Remegen, Genscript Bio, Wuxi Apptec up around 5%; Innocare up over 4%.
PHARMARON (03759) Schedules 30 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend
Bulletin Express  ·  03-16
PHARMARON (03759) Schedules 30 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend
PHARMARON Engages in Multiple Collaborations Across Various Sectors to Advance Business Objectives
Stock News  ·  03-12
PHARMARON Engages in Multiple Collaborations Across Various Sectors to Advance Business Objectives
Pharmaron (03759) States New Manufacturing Collaboration Falls Within Ordinary Business Scope; No Inside Information Identified
Bulletin Express  ·  03-12
Pharmaron (03759) States New Manufacturing Collaboration Falls Within Ordinary Business Scope; No Inside Information Identified
Eli Lilly Commits $3 Billion to Expand Weight-Loss Production in China
Stock News  ·  03-12
Eli Lilly Commits $3 Billion to Expand Weight-Loss Production in China
Pharmaron Shares Surge Over 5% on Lilly Manufacturing Pact for Orforglipron
Stock News  ·  03-12
Pharmaron Shares Surge Over 5% on Lilly Manufacturing Pact for Orforglipron

Introduction

Company Name.
PHARMARON
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Pharmaron Beijing Co Ltd is a China-based company mainly engaged in pharmaceutical research and development. The Company operates through five segments. The Laboratory Services segment includes laboratory chemistry and bioscience services, covering small molecule drugs, oligonucleotides, peptides, antibodies, antibody-drug conjugates, and cell and gene therapy products. The Chemical and Formulation Process Development and Manufacturing Services segment includes active pharmaceutical ingredient process development and manufacturing, as well as preformulation and formulation development. The Clinical Research Services segment includes international and domestic clinical research services. The Large Molecule and Cell and Gene Therapy Services segment includes large molecule drug discovery, development, and manufacturing services, as well as cell and gene therapy laboratory and gene therapy drug development and manufacturing services. The Company also operates through the others segment.
Issue price:
--